Claritev (CTEV) has just wrapped up FY 2025 with Q4 revenue of US$246.6 million and a basic EPS loss of US$4.88, alongside trailing 12 month revenue of US$965.4 million and a basic EPS loss of US$17.30. Over recent quarters, the company has seen revenue move from US$230.5 million in Q3 2024 to US$246.6 million in Q4 2025. Quarterly basic EPS has ranged from a loss of US$24.25 in Q3 2024 to a loss of US$3.81 to US$4.88 through 2025, setting a backdrop of significant revenue scale paired with pressured earnings. For investors, the latest print keeps the spotlight on Claritev’s path to improving margins and whether current loss levels can tighten from here.

See our full analysis for Claritev.

With the headline numbers on the table, the next step is to see how this earnings profile lines up against the main narratives around Claritev, including its unprofitability, modest growth, and perceived risk reward trade off.

See what the community is saying about Claritev

US$965 million in annual revenue with persistent losses

• On a trailing 12 month basis, Claritev generated US$965.4 million in revenue with a net loss of US$284.3 million and basic EPS of US$17.30 in losses, showing a sizeable business that is still running at a loss.
• Bulls point out that this revenue base, combined with AI and automation initiatives, could support long term earnings expansion, yet the current loss level gives them a high bar to clear:
  • Supporters focus on recurring deals and pipeline growth as a way to eventually turn that US$284.3 million loss into positive earnings, but the trailing figures show the company is not there yet.
  • The bullish view looks for higher margins over time, while the latest full year still reflects negative earnings across all four quarters, with quarterly net losses between US$62.6 million and US$80.6 million in 2025.

Claritev’s bullish backers argue that this scale plus AI driven efficiency could eventually turn losses into sizable profits, and they lay out how that might happen in the full bull case for the stock: 🐂 Claritev Bull Case

Loss trend tests the bearish worries

• Trailing revenue growth sits at 3.6% per year while losses have grown at about 27.9% per year over the past five years, and the latest trailing loss of US$284.3 million compares with much larger losses over the prior year, so the current data still shows unprofitable operations even if the loss size has been lower than earlier periods.
• Bears focus on rising regulatory and operating costs and the risk that Claritev stays unprofitable, and the reported numbers give them plenty to point to but also some nuance:
  • Critics highlight that analysts do not expect profitability within the next three years, which lines up with the current negative EPS across every 2025 quarter.
  • At the same time, the trailing net loss and EPS are smaller than the very large losses shown in earlier trailing data, which slightly softens, but does not remove, the bearish concern about long term margin pressure.

Skeptical investors see these continued losses as a key risk and outline how higher costs, regulation and client concentration could keep pressure on earnings in their full bear case: 🐻 Claritev Bear Case

Low 0.2x P/S with balance sheet stress

• Claritev trades on a P/S of 0.2x compared with 1.9x for peers and 2.2x for the US Healthcare Services industry, while carrying negative shareholders’ equity and a highly volatile share price, so the valuation looks low against sales but comes with clear balance sheet and market risk.
• The consensus style narrative sees this low multiple as a potential reward but flags that the financial profile can weigh on how the market prices the shares:
  • Supporters of the relative value angle point to the 0.2x P/S versus industry levels above 2x as a wide gap that could appeal to value focused investors.
  • On the other hand, negative equity and recent volatility fit with the picture of a company that is still unprofitable and whose modest 3.6% revenue growth rate trails the wider US market expectations of 10.3% a year.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Claritev on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both cautious and optimistic angles on Claritev laid out, this is the moment to look through the numbers yourself and decide where you stand, and you can ground that view by weighing its 1 key reward and 3 important warning signs.

Explore Alternatives

Claritev combines US$965.4 million in trailing revenue with consistent losses, negative equity, modest 3.6% revenue growth and a volatile share price that underlines its risk profile.

If that mix of ongoing losses and balance sheet pressure feels uncomfortable, it is worth checking companies in our solid balance sheet and fundamentals stocks screener (40 results) that pair financial resilience with earnings support.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.